251 related articles for article (PubMed ID: 32839463)
1. Integrated genomic analysis reveals mutated ELF3 as a potential gallbladder cancer vaccine candidate.
Pandey A; Stawiski EW; Durinck S; Gowda H; Goldstein LD; Barbhuiya MA; Schröder MS; Sreenivasamurthy SK; Kim SW; Phalke S; Suryamohan K; Lee K; Chakraborty P; Kode V; Shi X; Chatterjee A; Datta K; Khan AA; Subbannayya T; Wang J; Chaudhuri S; Gupta S; Shrivastav BR; Jaiswal BS; Poojary SS; Bhunia S; Garcia P; Bizama C; Rosa L; Kwon W; Kim H; Han Y; Yadav TD; Ramprasad VL; Chaudhuri A; Modrusan Z; Roa JC; Tiwari PK; Jang JY; Seshagiri S
Nat Commun; 2020 Aug; 11(1):4225. PubMed ID: 32839463
[TBL] [Abstract][Full Text] [Related]
2. ELF3 suppresses gallbladder cancer development through downregulation of the EREG/EGFR/mTOR complex 1 signalling pathway.
Nakamura T; Nishikawa Y; Shiokawa M; Takeda H; Yokode M; Matsumoto S; Muramoto Y; Ota S; Yoshida H; Okada H; Kuwada T; Marui S; Matsumori T; Maruno T; Uza N; Kodama Y; Hatano E; Seno H
J Pathol; 2023 Sep; 261(1):28-42. PubMed ID: 37345534
[TBL] [Abstract][Full Text] [Related]
3. ELF3 promotes gemcitabine resistance through PKMYT1/CDK1 signaling pathway in gallbladder cancer.
Yang L; Wang H; Guo M; He M; Zhang W; Zhan M; Liu Y
Cell Oncol (Dordr); 2023 Aug; 46(4):1085-1095. PubMed ID: 36988891
[TBL] [Abstract][Full Text] [Related]
4. ELF3, ELF5, EHF and SPDEF Transcription Factors in Tissue Homeostasis and Cancer.
Luk IY; Reehorst CM; Mariadason JM
Molecules; 2018 Aug; 23(9):. PubMed ID: 30200227
[TBL] [Abstract][Full Text] [Related]
5. Identification of MAP kinase pathways as therapeutic targets in gallbladder carcinoma using targeted parallel sequencing.
Li M; Chen L; Qu Y; Sui F; Yang Q; Ji M; Shi B; Chen M; Hou P
Oncotarget; 2017 May; 8(22):36319-36330. PubMed ID: 28422736
[TBL] [Abstract][Full Text] [Related]
6. A transcriptional repressive role for epithelial-specific ETS factor ELF3 on oestrogen receptor alpha in breast cancer cells.
Gajulapalli VN; Samanthapudi VS; Pulaganti M; Khumukcham SS; Malisetty VL; Guruprasad L; Chitta SK; Manavathi B
Biochem J; 2016 Apr; 473(8):1047-61. PubMed ID: 26920025
[TBL] [Abstract][Full Text] [Related]
7. Clinical and Pathological Characteristics of
Frank R; Scheffler M; Merkelbach-Bruse S; Ihle MA; Kron A; Rauer M; Ueckeroth F; König K; Michels S; Fischer R; Eisert A; Fassunke J; Heydt C; Serke M; Ko YD; Gerigk U; Geist T; Kaminsky B; Heukamp LC; Clement-Ziza M; Büttner R; Wolf J
Clin Cancer Res; 2018 Jul; 24(13):3087-3096. PubMed ID: 29615460
[No Abstract] [Full Text] [Related]
8. Elf3 drives β-catenin transactivation and associates with poor prognosis in colorectal cancer.
Wang JL; Chen ZF; Chen HM; Wang MY; Kong X; Wang YC; Sun TT; Hong J; Zou W; Xu J; Fang JY
Cell Death Dis; 2014 May; 5(5):e1263. PubMed ID: 24874735
[TBL] [Abstract][Full Text] [Related]
9. ELF3 is a negative regulator of epithelial-mesenchymal transition in ovarian cancer cells.
Yeung TL; Leung CS; Wong KK; Gutierrez-Hartmann A; Kwong J; Gershenson DM; Mok SC
Oncotarget; 2017 Mar; 8(10):16951-16963. PubMed ID: 28199976
[TBL] [Abstract][Full Text] [Related]
10. aPKCι promotes gallbladder cancer tumorigenesis and gemcitabine resistance by competing with Nrf2 for binding to Keap1.
Tian L; Lu Y; Yang T; Deng Z; Xu L; Yao W; Ma C; Li X; Zhang J; Liu Y; Wang J
Redox Biol; 2019 Apr; 22():101149. PubMed ID: 30822690
[TBL] [Abstract][Full Text] [Related]
11. Transcription factor 4 expression and correlation with tumor progression in gallbladder cancer.
Neogi K; Tewari M; Singh AK; Sharma K; Tej GNVC; Verma SS; Gupta SC; Nayak PK
J Cancer Res Ther; 2022; 18(3):668-676. PubMed ID: 35900539
[TBL] [Abstract][Full Text] [Related]
12. ELF3 is an antagonist of oncogenic-signalling-induced expression of EMT-TF ZEB1.
Liu D; Skomorovska Y; Song J; Bowler E; Harris R; Ravasz M; Bai S; Ayati M; Tamai K; Koyuturk M; Yuan X; Wang Z; Wang Y; Ewing RM
Cancer Biol Ther; 2019; 20(1):90-100. PubMed ID: 30148686
[No Abstract] [Full Text] [Related]
13. The genomic landscape of hepatoblastoma and their progenies with HCC-like features.
Eichenmüller M; Trippel F; Kreuder M; Beck A; Schwarzmayr T; Häberle B; Cairo S; Leuschner I; von Schweinitz D; Strom TM; Kappler R
J Hepatol; 2014 Dec; 61(6):1312-20. PubMed ID: 25135868
[TBL] [Abstract][Full Text] [Related]
14. Mutations in the KEAP1-NFE2L2 Pathway Define a Molecular Subset of Rapidly Progressing Lung Adenocarcinoma.
Goeman F; De Nicola F; Scalera S; Sperati F; Gallo E; Ciuffreda L; Pallocca M; Pizzuti L; Krasniqi E; Barchiesi G; Vici P; Barba M; Buglioni S; Casini B; Visca P; Pescarmona E; Mazzotta M; De Maria R; Fanciulli M; Ciliberto G; Maugeri-Saccà M
J Thorac Oncol; 2019 Nov; 14(11):1924-1934. PubMed ID: 31323387
[TBL] [Abstract][Full Text] [Related]
15. Nuclear factor erythroid 2-related factor 2 and β-Catenin Coactivation in Hepatocellular Cancer: Biological and Therapeutic Implications.
Tao J; Krutsenko Y; Moghe A; Singh S; Poddar M; Bell A; Oertel M; Singhi AD; Geller D; Chen X; Lujambio A; Liu S; Monga SP
Hepatology; 2021 Aug; 74(2):741-759. PubMed ID: 33529367
[TBL] [Abstract][Full Text] [Related]
16. E26 transformation (ETS)‑specific related transcription factor‑3 (ELF3) orchestrates a positive feedback loop that constitutively activates the MAPK/Erk pathway to drive thyroid cancer.
Chen H; Chen W; Zhang X; Hu L; Tang G; Kong J; Wang Z
Oncol Rep; 2019 Jan; 41(1):570-578. PubMed ID: 30365150
[TBL] [Abstract][Full Text] [Related]
17. E74-Like Factor 3 Is a Key Regulator of Epithelial Integrity and Immune Response Genes in Biliary Tract Cancer.
Suzuki M; Saito-Adachi M; Arai Y; Fujiwara Y; Takai E; Shibata S; Seki M; Rokutan H; Maeda D; Horie M; Suzuki Y; Shibata T; Kiyono T; Yachida S
Cancer Res; 2021 Jan; 81(2):489-500. PubMed ID: 33293429
[TBL] [Abstract][Full Text] [Related]
18. E74 like ETS transcription factor 3 (ELF3) is a negative regulator of epithelial- mesenchymal transition in bladder carcinoma.
Gondkar K; Patel K; Krishnappa S; Patil A; Nair B; Sundaram GM; Zea TT; Kumar P
Cancer Biomark; 2019; 25(2):223-232. PubMed ID: 31104013
[TBL] [Abstract][Full Text] [Related]
19. ETS transcription factor ESE1/ELF3 orchestrates a positive feedback loop that constitutively activates NF-κB and drives prostate cancer progression.
Longoni N; Sarti M; Albino D; Civenni G; Malek A; Ortelli E; Pinton S; Mello-Grand M; Ostano P; D'Ambrosio G; Sessa F; Garcia-Escudero R; Thalmann GN; Chiorino G; Catapano CV; Carbone GM
Cancer Res; 2013 Jul; 73(14):4533-47. PubMed ID: 23687337
[TBL] [Abstract][Full Text] [Related]
20. Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer.
Shibata T; Kokubu A; Gotoh M; Ojima H; Ohta T; Yamamoto M; Hirohashi S
Gastroenterology; 2008 Oct; 135(4):1358-1368, 1368.e1-4. PubMed ID: 18692501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
